The concomitant of non-classical stereotactic body radiotherapy with tislelizumab based on multidisciplinary modalities for leiomyosarcoma: A case report
Xiaona Han,Xiaotao Zhang,Yaru Lin,Jinying Li,Lan Yu,Li Liu,Wenzhi Tong,Xi Cheng,Xiao Li,Yanhao Liu
DOI: https://doi.org/10.1097/md.0000000000040278
IF: 1.6
2024-11-13
Medicine
Abstract:Bone and soft tissue sarcomas (BSTS) are rare and heterogeneous malignant tumors that originate from mesenchymal tissue, and include fibrosarcoma, Ewing sarcoma, rhabdomyosarcoma, leiomyosarcoma, liposarcoma, pleomorphic sarcoma, and synovial sarcoma. [ 1 ] Up to 50% of BSTS patients develop metastases in the course of the disease. [ 2 ] Although radical resection is curable for patients with BSTS, a significant portion of BSTS was inoperable. The treatments for inoperable BSTS include chemotherapy, radiotherapy, tyrosine kinase inhibitors, and immune checkpoint inhibitors (ICIs). Some patients may be eligible to receive surgery in conjunction with preoperative or postoperative radiotherapy. Preoperative radiotherapy can enhance the rate of R0 resection, reduce the extent of surgery, and potentially convert non-resectable lesions into resectable ones. Postoperative radiotherapy, on the other hand, can decrease the rate of local recurrence. Recently, the feasibility, safety, and efficacy of stereotactic body radiotherapy (SBRT) for the treatment of various primary or metastatic carcinomas, [ 3 ] including metastatic sarcoma, have been confirmed. [ 4 ] Compared with conventional radiotherapy, SBRT has advantages of higher biological effective dose (BED), fewer fractions, and superior precision. [ 5 ]
medicine, general & internal